🇺🇸 FDA
Drug

repotrectinib

Brand: AUGTYRO

approved

Quick answer

repotrectinib (AUGTYRO), is a pharmaceutical active ingredient, with approved status in the US.

Key facts

INN
repotrectinib
Brand
AUGTYRO
Route
ORAL
Formulation
CAPSULE

Related news

FDA Approves Augtyro: Bristol Myers Squibb’s Repotrectinib for ROS1-NSCLC
NewsNon-Small Cell Lung CancerApr 5, 2026

FDA Approves Augtyro: Bristol Myers Squibb’s Repotrectinib for ROS1-NSCLC

Bristol Myers Squibb's Augtyro, a novel treatment for ROS1-positive non-small cell lung cancer, has received FDA approval, marking a significant advancement in targeted therapies.

Dr. Sarah Mitchell

Frequently asked questions

What is repotrectinib?

repotrectinib (AUGTYRO), is a pharmaceutical active ingredient, with approved status in the US.

What is the brand name for repotrectinib?

AUGTYRO is a marketed brand name for repotrectinib. Check FDA Drugs@FDA for the current US label holder.